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Abstract: Type 2 diabetes mellitus (T2DM) is an ensemble of metabolic diseases that has reached
pandemic dimensions all over the world. The multifactorial nature of the pathology makes patient
management, which includes lifelong drug therapy and lifestyle modification, extremely challenging.
It is well known that T2DM is a preventable disease, therefore lowering the incidence of new T2DM cases
could be a key strategy to reduce the global impact of diabetes. Currently, there is growing evidence on
the efficacy of the use of medicinal plants supplements for T2DM prevention and management. Among
these medicinal plants, curcumin is gaining a growing interest in the scientific community. Curcumin
is a bioactive molecule present in the rhizome of the Curcuma longa plant, also known as turmeric.
Curcumin has different pharmacological and biological effects that have been described by both in vitro
and in vivo studies, and include antioxidant, cardio-protective, anti-inflammatory, anti-microbial,
nephro-protective, anti-neoplastic, hepato-protective, immunomodulatory, hypoglycaemic and
anti-rheumatic effects. In animal models, curcumin extract delays diabetes development, improves
β-cell functions, prevents β-cell death, and decreases insulin resistance. The present review focuses
on pre-clinical and clinical trials on curcumin supplementation in T2DM and discusses the peculiar
mechanisms by which curcumin might ameliorate diabetes management.
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1. Introduction
Diabetes has reached pandemic dimensions, affecting over 400 million people worldwide [1], and
it is also becoming relevant in developing countries. Among the huge and heterogeneous number
of patients with diabetes, type 2 diabetes mellitus (T2DM) represents the most prevalent form [2].
From the Global Burden of Diseases study (2016), it emerged that T2DM and its complications were
responsible for the 22% increase in disability in the last ten years, impacting significantly on public
health [3]. In recent years, enormous advances have been made in the field of diabetes prevention and
treatment and in glycaemic management, but the prevalence of cardiovascular complications remains
an important issue in T2DM patients [4]. Currently, the preferred therapies for T2DM treatment include
the use of anti-diabetic drugs, lifestyle intervention (healthy nutrition and daily physical activity) and
monitoring of arterial pressure and lipid profile. Effective prevention and treatment are needed to
optimally manage diabetes patients. It is well known that T2DM is a preventable disease [5]. A rigorous
prevention should be addressed to people with pre-diabetes or impaired glucose tolerance, who are at
high risk of T2DM development. Such prevention encompasses lifestyle modifications, such as starting
from a healthy diet and daily physical activity.
Currently, there is growing evidence on the efficacy of the use of medical plant supplements
for T2DM prevention and management [6–8]. Among these medical plants, curcumin is gaining a
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growing interest in the scientific community. Curcumin is an active molecule present in the rhizome of
Curcuma longa plant, also known as turmeric.
The biological and pharmacological effects of curcumin have been described by several in vitro
and in vivo studies, and include antioxidant, anti-inflammatory, anti-microbial, cardio-protective,
nephro-protective, anti-neoplastic, hepato-protective, immunomodulatory, hypoglycaemic and
anti-rheumatic effects [9–12].
Regarding diabetes, an animal study highlighted that curcumin and its analogues have a mechanism
of action similar to that of thiazolidinedione, an anti-diabetic drug, through peroxisome proliferator-
activated receptor-γ (PPAR-γ) activation [13]. Thus, curcumin may be effective in the regulation of
glycaemia and lipidaemia [14]—factors that play a key role in T2DM treatment. In particular, several
randomized controlled trials (RCTs) have been performed to study effects of curcumin on glycaemic
and lipid profiles in subjects with pre-diabetes [15,16] or T2DM [17–19].
The present review analyses the role of curcumin in T2DM prevention and treatment, focusing on
the preclinical and clinical trials.
1.1. Diabetes Mellitus and Its Complications
T2DM is one of the most terrible chronic diseases that affect human health. In recent years, in
developing countries, there was a 69% increase in the prevalence of diabetes, whereas in developed
countries, a 20% increase is expected between 2010 and 2030 [20]. In particular, T2DM is a chronic
and metabolic disease characterised by defects in pancreatic insulin secretion and (or) insulin effect on
target tissues, generating a persistent state of hyperglycaemia, inducing metabolic alteration, cell-death
and inflammation. The increased morbidity and mortality rates related to T2DM are often associated
with vascular complications, such as cardiovascular diseases [21], nephropathy [22], retinopathy [23],
endothelial dysfunction, dyslipidaemia and an increase of oxidative stress which is also due to
inflammation [24]. In fact, diabetes is characterised by a chronic inflammation and insulin resistance due
to the enhancement of pro-inflammatory cytokines production by monocytes infiltrate in adipose tissue.
This condition is worsened by angiopoietin-like protein 2 (ANGPTL2), highly expressed in macrophages
and adipose tissue, because of its role in T-lymphocytes/macrophages activation and accumulation,
promoting impaired insulin response. Moreover, high serum ANGPTL2 levels are involved in the
development of renal diabetic disease, because of its positive correlation with albumin-to-creatinine ratio
and negative correlation with glomerular filtration rate (GFR) [25]. Among microvascular complications
approximately 50% of T2DM patients developed a diabetic peripheral neuropathy, a chronic and
progressive disorder affecting the peripheral nervous system and characterised by allodynia, pain
and paraesthesia symptoms [26], caused by axonal degeneration and segmental demyelination [27].
Moreover, patients with T2DM are at high risk of infections, indirectly caused by diabetic neuropathy,
impaired glycaemic control, and immune system dysregulation [28,29]. Diabetic patients are more prone
to develop common infections, like cystitis, enteric infections, external otitis, pneumonia, appendicitis
and peritonitis as well as rare and severe infections, such as emphysematous pyelonephritis [30,31].
Furthermore, T2DM patients have higher mortality rates for sepsis compared to other individuals [32].
1.2. Curcumin: Structure, Biological Activity and Bioavailability
Turmeric plant, commonly utilised in food preparation as a spice (present also in curry powder)
and in the scientific community, is recognised as Curcuma longa. This type of plant is characterised by
orange tuberous rhizomes and is widely cultivated in South East Asia, where it is used as a natural
therapeutic remedy for various pathological conditions since ancient times. The peculiar characteristics
that have focused scientists’ attention on curcumin as a nutraceutical are the following: the antioxidant
and anti-inflammatory activities and the safety of its pharmacological profile [33]. In addition, curcumin
has a potential role both in the prevention and treatment of several diseases because of its variety
of actions: anti-bacterial, anti-diabetic, anti-viral and anti-cancer activities [34,35]. This mechanism
of action on several molecular pathways is due to the peculiar chemical structure of curcumin, able
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to have huge numbers of molecular targets. Among the biological effects, the inhibition of reactive
oxygen species (ROS) production plays a key role, in particular for inflammatory diseases. In turmeric,
several compounds coexist, structurally related to curcuminoids, including curcumin as the main
active and most important constituent. The main curcuminoids in commercial turmeric extracts are
curcumin (≈75%), demethoxycurcumin (≈20%), and bisdemethoxycurcumin (≈5%) [36].
Bioavailability represents the major issue in the use of curcumin as a nutritional supplement. In fact,
different studies on curcumin bioavailability and pharmacokinetics recognized its low absorption rate
in the gastro-intestinal tract and its rapid body elimination [37]. Several animal studies, especially in
rodents, have described the rapid metabolism, low absorption, bio-distribution and rapid excretion
of curcumin (oral administration) [38–40]. For these reasons, recent studies focused on developing
new techniques to solve these issues and improve curcumin bioavailability, intestinal absorption and
body distribution. These approaches include, for example, micellas, nanoparticles, liposomes and
phospholipid complexes [41]. Among these approaches, one of the most promising is phytosome
technology, which proved effective in the improvement of curcumin oral bioavailability. Moreover, its
particular structure enhanced pharmacokinetic parameters after the oral administration of curcuminoids.
Phytosomal curcumin efficacy and tolerability have been proven in the improvement of inflammatory
diseases, such as cancer, cardiovascular disease and osteoarthritis. Importantly, there is a body of
evidence for the clinical use of phytosomal curcumin in patients with solid tumours, uveitis, benign
prostate hyperplasia, diabetic micro-angiopathy and retinopathy [9,42]. Other technologies that showed
advantages in increasing polyphenols solubility and bioavailability include food lipid nanoparticles,
in particular solid lipid nanoparticles. For example, Sun and colleagues discovered that curcumin
lipid nanoparticles could lengthen in vitro cellular uptake and anti-tumour activity and increase
the in vivo bioavailability of the loaded curcumin [43]. Moreover, curcumin encapsulation in camel
β-casein micelle increased the solubility of curcumin by over 2000-fold [44]. This specific encapsulation
influences curcumin antioxidant activity, cytotoxicity in an in vitro model of human leukemia and
anti-proliferation activity against in vitro models of human colorectal and pancreatic cancer [45,46].
Various studies also demonstrated an increased oral bioavailability after curcumin nanoemulsion
incorporation, facilitating its application as phytochemical in humans [47].
2. Curcumin and Type 2 Diabetes Mellitus
2.1. Molecular Mechanisms of Curcumin in T2DM
Several studies have shown that curcumin improves the pathologic events in T2DM through different
mechanisms and multiple molecular targets (see Table 1). In particular, curcumin is involved in the
regulation of lipid metabolism. Curcumin reduces the gene expression of transcription factors involved in
hepatic lipogenesis, such as the sterol regulatory element-binding protein 1c (SREBP1c), which promotes
cholesterol synthesis and the carbohydrate response element-binding protein (ChREBP) [48]. Moreover,
curcumin increases the activity of lipid mobilization enzymes, including carnitine palmitoyltransferase 1
(CPT1) and acyl-CoA cholesterol acyltransferase (ACAT).
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Table 1. Curcumin and T2DM: molecular and cellular mechanisms discovered in in vivo and in vitro models.
Dosage Cellular and Molecular Effects T2DM Prevention and Treatment Potential In vitro/in vivo Study Country/Reference
Standard diet with 0.2 g/kg of curcumin
for 6 weeks
↓ SREBP1c, ChREBP;
↑ CPT1, ACAT
Regulation of lipid metabolism diabetic db/db mice Republic of
Korea/[48]
Standard diet with 0.75% of curcumin for
8 weeks
↑ PPAR-γ via AMPK activation;
↓ lipid peroxidation
Anti-oxidant activity db/db mice Mexico/[49]
30–90 mg/kg for 31 days
- anti-hyperglycaemic and
anti-hyperlipidaemic effect
- ↓blood glucose and lipid levels and
- ↑the levels of hepatic antioxidants
anti-hyperglycaemic and
anti-hyperlipidaemic effect
Streptozotocin-induced diabetic rats Brasil/[50,51]
100 mg/kg of body weight for 7 weeks;
0.01–1 µM for 24 h
↓MCP-1, IL-6, HbA1c, TNF-α and lipid peroxidation Hypoglycaemic, anti-inflammatory and lipid
lowering effects - Streptozotocin-induced
diabetic rats
- U937 monocytes
USA/[52]
- Curcumin 0.5% w/w;
- Curcumin 0.2% plus diet;
- 0.05 g/100 g diet;
- 80 mg/kg for 60-75 days;
- 50, 150, or 250 mg/kg for 7 weeks;
- 100 mg/kg for 28 days;
- 20 mg/kg for 45 days
↓ glycaemia and dyslipidaemia in high fat-fed rats Hypoglycaemic effect Streptozotocin-induced rats fed with
high-cholesterol diet (HCD)
Egypt/[53]]
India/[54]
South Korea/[55]
Egypt/[56]
China/[57]
India/[58]
Egypt/[59]
80 mg/kg of body weight for 45 days ↓ blood glucose
↑ antioxidant defences
Hypoglycaemic and anti-oxidant effects STZ-induced diabetic rats India/[60]
Curcumin 20 µM ↓MCP-1, IL-1β, TNFα, IL-6 and COX2 Anti-inflammatory effect Adipocytes USA/[61]
200 mg/kg of body weight for 16 weeks ↑ Bcl-2;
↓ Bax, caspase-3
Anti-apoptotic effect Streptozotocin-induced diabetic rats China/[62]
- 2.5, 5, or 10 µM
- 5 mg/kg once every 2 days for
12 weeks.
↓ JNK phosphorylation Anti-apoptotic and Anti-inflammatory effect
- Primary cultures of neonatal
rat cardiomyocytes;
- Streptozotocin-induced
diabetic rats
USA/[63]
China/[64]
↓ = decrease, ↑ = increase.
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In addition, an animal study found that curcumin is involved in the pathological fat accumulation
in the liver through the up-regulation of PPAR-γ via AMPK activation [49]. Moreover, the
anti-hyperglycaemic and anti-hyperlipidaemic effect of curcumin has been demonstrated in streptozotocin
(STZ)-induced diabetic rats after curcumin supplementation (30–90 mg/kg of body weight) in a formulation
of yogurt for a period of 31 days [50]. Recently, the same research group described that isolated treatments
using curcumin (90 mg/kg of body weight) plus insulin (1 U/day vs. 4 U/day) decreased blood glucose,
biomarkers of liver and kidney damage, improved lipid profile and hepatic antioxidants levels [51].
Curcumin supplementation (50 or 100 mg/kg of body weight) in STZ-induced diabetic rats decreased
hyperglycaemia and vascular inflammation through the inhibition of MCP-1, IL-6, HbA1c, TNF-α and
lipid peroxidation [52]. Moreover, a lot of data have shown that curcumin can improve insulin sensitivity
through decreasing glycaemia and dyslipidaemia in high fat-fed rats [53–59].
Also, oxidative stress has been related to the pathogenesis of T2DM. The protective effect of
curcumin against oxidative damage has been proven. Curcumin reduces lipid peroxidation through
the normalization of antioxidant enzyme levels, such as superoxide dismutase, catalase and glutathione
peroxidase [49]. The administration of tetrahydrocurcumin (80 mg/kg of body weight), a curcumin
derivative, for a period of 45 days decreased fasting blood glucose (−55%) and STZ-induced diabetic
rats increased their antioxidant defences [60].
Beyond oxidative stress, inflammation also plays a key role in the development of T2DM and its
complications. Several studies on animal models of diabetes showed that Curcumin administration
decreased the number of inflammatory factors in serum, such as IL-6, TNF-α, MCP-1, and it suppressed the
NF-κB signalling pathway, defending against inflammation [21,52]. Also, in vivo studies demonstrated
the beneficial effect of curcumin on adipose tissue through the inhibition of several pro-inflammatory
mediators, such as MCP-1, IL-1β, TNFα, IL-6 and COX2 [61]. Finally, many authors have confirmed
the anti-apoptotic effect of curcumin in diabetic rats with cardiomyopathy. In particular, apoptosis is
stimulated in the hearts of rat diabetic cardiomyopathy and curcumin treatment significantly decreased
myocardial cell apoptosis [62]. Moreover, curcumin prevents apoptotic and inflammatory process in
cardiomyocytes through the inhibition of JNK phosphorylation [63,64].
2.2. What We Know from Clinical Trials?
Currently, several animal models [65] and human subjects [66–68] have shown curcumin tolerability
and safety, also at high doses (oral administration of 12 g/day). However, to date it is not recommended
to prescribe curcumin supplementation in subjects under particular conditions, such as pregnant or
lactating women, children or in patients with anaemia or liver disease due to few safe studies on
humans. In animal models, on the other hand, there is a rich scientific literature on oral curcumin safety
and tolerability also in delicate conditions [69]. Several in vivo studies have shown oral curcumin
safety during pregnancy, also reporting non-mutagenic and non-genotoxic effects [70,71]. Lu and
colleagues reported that high curcumin supplementation (100 mg/kg) could also improve glucose and
insulin intolerance through activating the AMPK pathway in gestational diabetes mice [72]. Curcumin
can be considered as an alternative treatment for gestational diabetes, but further studies are needed.
Another open question refers to curcumin interaction with conventional drugs. In fact, some studies
identified the effect of curcumin as cytochrome P450 inhibitor [73], conferring potential interaction
with anticoagulants, cardiovascular drugs, antibiotics, anti-depressant and anti-cancer drugs [74,75].
Regarding curcumin use in T2DM prevention and treatment, the first data from clinical trials are
reported in Table 2. Mohammed et al. recently reviewed published studies focused on the hypoglycaemic
action of the spice-derived bioactive ingredients. Despite many of the analysed ingredients showing
weak hypoglycaemic effects, curcumin has demonstrated promising hypoglycaemic potential even if
further scientific studies are needed to outline safe therapeutic protocols as hypoglycaemic adjuvant [76].
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Table 2. Curcuminoids supplementation in pre-diabetes and T2DM patients clinical trials.
Dosage/Treatment Period Clinical Trial Type Study Groups Characteristics Supplementation Beneficial Effects Supplementation Adverse Effects Country/Reference
Curcuminoids: 250 mg/day
for 9 months
Randomized, double-blinded,
placebo-controlled trial
240 prediabetic subjects:
- n = 120 placebo group;
- n = 120 curcuminoids group
- T2DM prevention: 0% T2DM incidence in the treated
group vs. 16.4% incidence in the placebo group;
- β-cells function improvement
- ↓C-peptide level;
- ↑ HOMA-β level;
- ↑ adiponectin level;
- ↓ HOMA-IR (insulin resistance).
Major symptoms: none.
Minor symptoms: itching (one
subject), constipation (two subjects),
and vertigo (one subjects)
Thailand/[77]
NCB-02 (curcuminoids):
300 mg for 8 weeks
Randomized, parallel-group,
placebo-controlled trial
67 T2DM patients:
- n = 21 placebo group
- n = 22 atorvastatin group
- n = 23 NCB-02 group
- endothelial function improvement
- ↓malondialdehyde;
- ↓ endothelin-1;
- ↓ IL-6;
- ↓ TNF-α.
Major symptoms: none.
Minor symptoms: mild diarrhoea
(two subjects)
India/[78]
Curcuminoids: 475 mg for 10
days
Comparison between glyburide
treatment and glyburide plus
curcuminoids treatment
8 T2DM patients treated with
glyburide (5mg) ↓LDL, VLDL, triglycerides;
↑HDL;
glycaemic control imprevement (lower blood glucose
levels after breakfast, lunch and dinner)
Major symptoms: none.
Minor symptoms: none.
India/[41]
Curcuminoids: 500 mg/day
plus piperine 5 mg/day for
3 months
Randomized, double-blinded,
placebo-controlled trial
100 T2DM patients:
- n = 50 placebo group;
- n = 50 curcuminoids group
- ↓ blood glucose level;
- ↓ C-peptide level;
- ↓ HbA1c;
- ↓ alanine aminotransferase and
aspartate aminotransferase.
Major symptoms: none.
Minor symptoms: none.
Iran/[79]
Curcuminoids: 1000 mg /day
plus 10 mg of piperine/day for
12 weeks
Randomized, double-blinded,
placebo-controlled trial
100 T2DM patients:
- n = 50 placebo group;
- n = 50 curcuminoids group
- ↓ leptin;
- ↓ TNF-α;
- ↓ leptin:adiponectin ratio;
- ↑ adiponectin.
Major symptoms: none.
Minor symptoms: none.
Iran/[80]
Curcuminoids: 300 mg/day
for 3 months
Randomized, double-blinded,
placebo-controlled trial
100 overweight/obese T2DM patients:
- n = 50 placebo group;
- n = 50 curcuminoids group
- ↓ fasting glycaemia;
- ↓ HOMA-IR (insulin resistance);
- ↓ HbA1c;
- ↑ lipoprotein lipase activity;
- ↓ FFA and triglycerides.
Major symptoms: none.
Minor symptoms: none.
China/[18]
↓ = decrease, ↑ = increase.
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A randomized, double-blinded, placebo-controlled trial by Chuengsamarn and colleagues [77]
included 240 prediabetic subjects. All subjects were randomly assigned to receive either curcumin
(250 mg curcuminoids/day) or placebo capsules for 9 months. After this period, 16.4% of subjects in
the placebo group were diagnosed with T2DM, whereas in the group treated with curcumin, none
were diagnosed with diabetes. Moreover, in the study group, an improvement in the overall function
of β-cells, with lower C-peptide and higher HOMA-β (homeostasis model assessment), emerged.
In addition, subjects treated with curcumin, compared to the placebo group, showed higher adiponectin
levels and lower insulin resistance.
Previously, Usharani and colleagues reported an improvement in the antioxidant status, comparable
to that of atorvastatin, in T2DM patients supplemented with curcumin capsules (300 mg) for 8 weeks [78].
More recently, Neerati et al. reported that curcumin supplementation (475 mg) for a period of
10 days attenuated hyperglycaemia and hyperlipidaemia in T2DM subjects treated with glyburide.
In particular, the low-density lipoprotein, very-low-density lipoprotein and triglycerides were
significantly decreased, and the high-density lipoprotein content increased [41].
Panahi et al. performed an RCT to assess the effect of nutritional education in combination with
curcumin (curcumin 500 mg/day in association with piperine 5 mg/day) or placebo in T2DM patients.
A total of 100 T2DM patients aged between 18–65 years were enrolled, and glycaemic, hepatic and
inflammatory markers were recorded at baseline and after 3 months. The main results reported a
significant reduction in serum levels of C-peptide, HbA1c and glucose in the curcumin-treated group
versus the placebo group. Despite expectations, there was no significant difference in the levels of
C-reactive protein, an inflammation marker, between the two groups [79]. A previous RCT by the same
research group focused on curcuminoid effects on ghrelin, adiponectin, leptin, and TNFα in a cohort of
118 T2DM patients. In particular, curcumin supplementation (curcumin 1000 mg with 10 mg piperine
daily) for 12 weeks was effective on adiponectin increase, whereas the leptin/adiponectin ratio (an index
of atherosclerosis degree) and leptin levels decreased independently by the weight loss, reflecting a
reduction in the inflammatory TNFα marker [80]. The results of these two trials highlighted a beneficial
and synergistic effect of curcumin and piperine on glycaemic, inflammatory and hepatic markers in
T2DM patients. In particular, piperine seems to significantly improve curcumin intestinal absorption
and bioavailability [81].
Na and colleagues performed an RCT to study the effect of curcumin on human blood glucose
improvement that they previously found on diabetic rats [57]. One-hundred overweight/obese T2DM
patients were randomly divided to the curcumin supplementation (300 mg/day) group or the placebo
group for a period of three months. In this trial, the curcumin supplementation group obtained a
significant reduction of fasting glycaemia, insulin resistance and HbA1c, together with a decrease in
serum triglycerides and total free fatty acids (FFAs), and an improve in lipoprotein lipase activity.
In particular, the glucose-lowering effect of curcumin is partially due to a decrease in serum FFA, which
may result from promoting fatty acid oxidation and utilisation [18].
3. Conclusions
Numerous in vitro and in vivo studies have provided strong evidence for investigating curcumin
efficacy against type 2 diabetes mellitus. Data reported in this review show that curcumin has therapeutic
potential to counteract diabetes and its complications. All the described studies have shown that doses
of up to 12 g per day of curcumin are safe, tolerable and non-toxic. The functional mechanism by which
curcumin exerts its effect appears to be the modulation of many signalling molecules. However, this
mechanism is not completely clear, due to the complexity of the disease. Based on clinical trials, the
clinical efficacy of curcumin seems promising. However, this nutraceutical has poor bioavailability and
limited adverse effects reported, representing a major limitation to the therapeutic utility.
Studies on the effect of curcumin on the control of glycaemia and lipid accumulation are lacking,
especially in pre-diabetes patients. Moreover, the majority of studies performed tested different
preparations of curcumin, especially in combination with other molecules (e.g., piperine), but studies
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testing pure curcumin are limited. Recently, the results of a meta-analysis have shown the beneficial
effects of curcumin and its preparation in Asian pre-diabetes and T2DM patients [7], because most
clinical trials were performed on this population. In particular, curcumin appears to be really effective
on glycaemic parameters, especially on HbA1c levels. Evaluating all the data in the scientific literature,
further clinical trials will be needed to evaluate the effects of curcumin and its specific dosage on
glycaemic outcomes, particularly in pre-diabetes and T2DM patients.
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